NCT03359213 - A Study of JR-141 in Patients With Mucopolysaccharidosis II (BR21) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 26, 2018

Primary Completion Date

October 4, 2019

Study Completion Date

October 4, 2019

Conditions

Mucopolysaccharidosis II

Interventions

DRUG

JR-141

IV infusion (lyophilized powder), 1.0 mg/kg/week

DRUG

JR-141

IV infusion (lyophilized powder), 2.0 mg/kg/week

DRUG

JR-141

IV infusion (lyophilized powder), 4.0 mg/kg/week

Trial Locations (2)

Grupo de Pesquisa Clínica em Genética Médica - HCPA, Porto Alegre

Igeim - Unifesp, São Paulo